Molecular Devices partners with SEED Biosciences to offer DispenCell Single-Cell Dispenser in North America and Asia, expanding leadership in cell line development
Molecular Devices, LLC., a leading provider of high-performance life science solutions, has entered into a partnership with SEED Biosciences Ltd, a solutions company for single-cell assays. Molecular Devices is now an exclusive commercial supplier of the award-winning DispenCell Single-Cell Dispenser – an automated laboratory instrument designed for fast, easy, and gentle single-cell isolation – in the United States and Asia, with reseller rights in most of Europe.
“Integrating the DispenCell Single-Cell Dispenser into our portfolio of automated, end-to-end solutions for cell line development workflows will further strengthen our ability to help the scientific community industrialize biology,” said Susan Murphy, President of Molecular Devices. “With an accessible price point and ease of use, the DispenCell Single-Cell Dispenser pairs particularly well with our CloneSelect Imager FL to enhance, streamline, and assure monoclonality verification right from the start.”
Accurate single-cell isolation with immediate, traceable proof of monoclonality is critical to a successful cell line development process. However, isolating a monoclonal cell population by the manual and time-consuming limiting dilution method – which can include three rounds of cloning – leads to high variability in results. Alternatively, the automated DispenCell Single-Cell Dispenser requires just one round of cloning and a single plate, offering significant efficiency improvements.
“Selecting Molecular Devices as an exclusive provider was an easy decision to make, as we share a purpose to help scientists develop safer, more efficient biotherapies faster, and at lower costs,” said Georges Muller, SEED Biosciences’ CEO and co-founder. “Expanding our reach through Molecular Devices and with the strength of our combined technologies, we will enable more clients to overcome bottlenecks and maximize their single-cell cloning, CRISPR gene-editing, and single-cell omics assays as well as their cell line development workflows.”